Orthofix Medical Inc. (OFIX) Presents at UBS Global Healthcare Conference 2025 Transcript

Orthofix Medical Inc. ( OFIX ) UBS Global Healthcare Conference 2025 November 11, 2025 1:15 PM EST Company Participants Massimo Calafiore - President, CEO & Director Julie Dewey - Chief Investor Relations & Communications Officer Conference Call Participants Danielle Antalffy - UBS Investment Bank, Research Division Presentation Danielle Antalffy UBS Investment Bank, Research Division All right. Good afternoon, everyone.

Seeking Alpha • Nov 11, 2025

Orthofix Medical Inc. (OFIX) Q3 2025 Earnings Call Prepared Remarks Transcript

Orthofix Medical Inc. ( OFIX ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Julie Dewey - Chief Investor Relations & Communications Officer Massimo Calafiore - President, CEO & Director Julie Andrews - Chief Financial Officer Conference Call Participants Thomas Stephan - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Petusky - Barrington Research Associates, Inc., Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today.

Seeking Alpha • Nov 4, 2025

Orthofix Reports Third Quarter 2025 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this release exclude the impact of the Company's decision to discontinue its M6™ product lines. Highlights Third quarter.

Business Wire • Nov 4, 2025

Orthofix (OFIX) Beats Q3 Earnings and Revenue Estimates

Orthofix (OFIX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.07 per share a year ago.

Zacks Investment Research • Nov 4, 2025

Orthofix to Participate in Upcoming Investor Conferences

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Massimo Calafiore, President and Chief Executive Officer, and Julie Andrews, Chief Financial Officer, will participate in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FL, November 11, 2025, at 1:15 pm Eastern Time Stifel Healthcare Conference in New York, NY, November 12, 2025, at 10:00 am Eastern Time Jefferies.

Business Wire • Oct 15, 2025

Orthofix to Report Third Quarter 2025 Financial Results

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025, before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day. Interested parties may access the conference call by dialing (888) 596-4144 in the U.S., and (646) 968-2525 in all other locations, and referenci.

Business Wire • Oct 14, 2025

FMS vs. OFIX: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical - Instruments sector might want to consider either Fresenius (FMS) or Orthofix (OFIX). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Oct 7, 2025

ORTHOFIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Orthofix Medical Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Orthofix (OFIX) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  Orthofix between October 11, 2022, and September 12, 2023 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

GlobeNewsWire • Sep 4, 2025

FMS vs. OFIX: Which Stock Should Value Investors Buy Now?

Investors interested in Medical - Instruments stocks are likely familiar with Fresenius (FMS) and Orthofix (OFIX). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Aug 7, 2025

Orthofix (OFIX) Q2 Revenue Rises 2%

Orthofix (OFIX) Q2 Revenue Rises 2%

The Motley Fool • Aug 6, 2025